Search research articles
Contact Us
Filters
Showing results (101-110 of 308) with videos related to
Page
of 31
Sort By:
Blood Advances
|
June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
Anthony S Stein, Richard A Larson, Andre C Schuh, et al.
The Journal of Clinical Investigation
|
August 22, 2002
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus
David M Koelle, Zhi Liu, Christopher M McClurkan, et al.
Immunology and Cell Biology
|
May 14, 2014
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice
Tanja Bedke, Rossana G Iannitti, Antonella De Luca, et al.
Journal of Leukocyte Biology
|
August 13, 2015
Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs
Carsten Berges, Tanja Bedke, Claudia Stuehler, et al.
Experimental Hematology & Oncology
|
May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.
Haematologica
|
February 8, 2020
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma
Max S Topp, Johannes Duell, Ana Maria Abajo Guijarro, et al.
Haematologica
|
February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
Leo Rasche, Johannes Duell, Inês C Castro, et al.
Blood
|
December 3, 2005
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus
Olaf Beck, Max S Topp, Ulrike Koehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Rheumatology and Therapy
|
August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
Philip J Mease, Herbert Kellner, Akimichi Morita, et al.
Page
of 31
Search research articles
Search
Showing results (101-110 of 308) with videos related to
Sort By:
Page
of 31
Blood Advances
|
June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia
Anthony S Stein, Richard A Larson, Andre C Schuh, et al.
The Journal of Clinical Investigation
|
August 22, 2002
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus
David M Koelle, Zhi Liu, Christopher M McClurkan, et al.
Immunology and Cell Biology
|
May 14, 2014
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice
Tanja Bedke, Rossana G Iannitti, Antonella De Luca, et al.
Journal of Leukocyte Biology
|
August 13, 2015
Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs
Carsten Berges, Tanja Bedke, Claudia Stuehler, et al.
Experimental Hematology & Oncology
|
May 24, 2017
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, et al.
Haematologica
|
February 8, 2020
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma
Max S Topp, Johannes Duell, Ana Maria Abajo Guijarro, et al.
Haematologica
|
February 1, 2015
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6
Leo Rasche, Johannes Duell, Inês C Castro, et al.
Blood
|
December 3, 2005
Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus
Olaf Beck, Max S Topp, Ulrike Koehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Rheumatology and Therapy
|
August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
Philip J Mease, Herbert Kellner, Akimichi Morita, et al.
Page
of 31